Lv1
78 积分 2025-07-03 加入
OP0189 SAFETY AND EFFICACY OF INEBILIZUMAB IN IgG4-RELATED DISEASE ACROSS VARIOUS PARTICIPANT DEMOGRAPHICS: SUBGROUP ANALYSIS FROM THE MITIGATE STUDY
5天前
已关闭
Inebilizumab for Treatment of IgG4-Related Disease
5天前
已完结
Recent advances in IgG4-related autoimmune pancreatitis
6天前
已完结
Rationale Diagnostik und Differenzialdiagnosen bei IgG4-assoziierten Erkrankungen
6天前
已完结
Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time
10天前
已完结
Current Treatment Options for Diabetic Retinal Disease
10天前
已完结
C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review
12天前
已完结
A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan
16天前
已关闭
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy
16天前
已关闭
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
17天前
已完结
皖公网安备34019202002308
